Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial | Zendy

Vered Stearns | Zendy; JudithAnne W. Chapman | Zendy; X. Cynthia | Zendy; Matthew J. Ellis | Zendy; James N. Ingle | Zendy; Kathleen I. Pritchard | Zendy; G. Thomas Budd | Zendy; Manuela Rabaglio | Zendy; George W. Sledge | Zendy; Aurélie Le Maître | Zendy; Jessica Kundapur | Zendy; Pedro Emanuel Rubini Liedke | Zendy; Lois E. Shepherd | Zendy; Paul E. Goss | Zendy

Open Access

Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial

Author(s) -

Vered Stearns,

JudithAnne W. Chapman,

X. Cynthia,

Matthew J. Ellis,

James N. Ingle,

Kathleen I. Pritchard,

G. Thomas Budd,

Manuela Rabaglio,

George W. Sledge,

Aurélie Le Maître,

Jessica Kundapur,

Pedro Emanuel Rubini Liedke,

Lois E. Shepherd,

Paul E. Goss

Publication year - 2014

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2014.57.6926

Subject(s) - medicine , anastrozole , exemestane , vasomotor , aromatase inhibitor , breast cancer , adverse effect , common terminology criteria for adverse events , tamoxifen , cancer , surgery

Treatment-emergent symptoms with adjuvant tamoxifen and aromatase inhibitors (AIs) have been associated with superior recurrence-free survival (RFS). We hypothesized that MA.27 anastrozole- or exemestane-treated patients with new or worsening vasomotor and/or joint symptoms would have improved RFS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research